Conversely, hepatic PPARγ overexpression results in exacerbated steatosis by mechanisms involving activation of lipogenic genes, thereby increasing de novo lipogenesis and hepatic triglyceride content [16]. The gene discussed is PPARG; the disease is steatosis.